Hong Kong-listed Chinese drug firms set to turn corner on rising sales, licensing deals
Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures
“Despite domestic challenges, particularly drug pricing pressure, the earnings performance of innovative drugs should still fare well in China in 2025,” said Tony Ren, head of Asia Healthcare Research at Macquarie Capital.
Revenue at Innovent, best known for its cancer treatment drug development, jumped about 45 per cent in 2025 to roughly 11.9 billion yuan, marking a “historic milestone”, the company said in a filing on February 4. The company, which launched six new products last year, releases its earnings release in late March.
Founded in 2011, Innovent was one of the first batch of firms to go public in 2018 under a new Hong Kong listing rule that let pre-revenue and loss-making drug and medical device developers raise capital.